Journal of Bone and Mineral Metabolism

, Volume 29, Issue 5, pp 588–597

Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36

  • Takuo Fujita
  • Mutsumi Ohue
  • Mikio Nakajima
  • Yoshio Fujii
  • Akimitsu Miyauchi
  • Yasuyuki Takagi
Original Article


Back and knee pain is a widespread health problem and a serious threat to the quality of life (QOL) in middle-aged and older adults, as it frequently accompanies osteoporosis and osteoarthritis. In order to compare the effects of elcatonin and risedronate on such pain, 20 units of elcatonin was intramuscularly injected to 18 patients, and 5 mg of risedronate was orally administered daily to 20 others with similar backgrounds. Exercise-induced pain was analyzed by measuring the fall of skin impedance by electroalgometry (EAM), and subjective pain was recorded by a visual rating system (VRS) on a scale of 0 (no pain) to 100 (unbearable pain). In patients treated with elcatonin, the mean EAM-estimated pain was significantly reduced after 4, 5 and 6 months of treatment, and the VRS score after 3, 5 and 6 months, indicating a significant analgesic effect. In the risedronate group, however, improvement was less remarkable. Two-way analysis of variance using pain as a dependent variable and treatment group and time as independent variables revealed a significantly greater effect of elcatonin over risedronate on both the EAM and VRS scores, and the influence of treatment time on pain was indistinguishable between the two treatment groups. Effect of exercise load on pain was less on knee load than knee and spine load and spine load, but indistinguishable between the two groups. Changes in QOL were evaluated by the SF-36 system. Norm-based scoring showed significant improvements in 3 of 4 categories for elcatonin and in 2 of 4 for risedronate, suggesting comparable effects on the physical aspects of QOL, whereas responses to emotionally and socially directed questions indicated significant improvements in all 4 categories for risedronate, but none for elcatonin, suggesting a more physical than emotional component in elcatonin effects compared to risedronate.


Elcatonin Risedronate Pain Electroalgometry (fall of skin impedance) SF-36 


  1. 1.
    Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y (2001) Fall of skin impedance and bone and joint pain. J Bone Miner Metab 19:175–179PubMedCrossRefGoogle Scholar
  2. 2.
    Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y (2001) Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 19:251–256PubMedCrossRefGoogle Scholar
  3. 3.
    Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi M (2009) Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. J Bone Miner Metab 27:234–239PubMedCrossRefGoogle Scholar
  4. 4.
    Fujita T, Fujii Y, Munezane H, Ohue M, Takagi Y (2010) Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. J Bone Miner Metab 28:477–484. doi:101007/S00774-009-0155-6 PubMedCrossRefGoogle Scholar
  5. 5.
    Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23:540–551PubMedCrossRefGoogle Scholar
  6. 6.
    Pun KK, Chan LW (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205–209PubMedGoogle Scholar
  7. 7.
    Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Qvist P, Christiansen C (2006) Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthr Cartil 14:617–624PubMedCrossRefGoogle Scholar
  8. 8.
    Karsdal MA, Sondergaard BC, Arnold M, Christiansen C (2007) Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 1117:181–195PubMedCrossRefGoogle Scholar
  9. 9.
    Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN 01928173]. Arthritis Res Ther 7:625–633CrossRefGoogle Scholar
  10. 10.
    Bingham CO III, Buckland-Wright JC, Grnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54:3494–3507PubMedCrossRefGoogle Scholar
  11. 11.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRefGoogle Scholar
  12. 12.
    Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51:1037–1044PubMedCrossRefGoogle Scholar
  13. 13.
    Fukuhara S, Were JE Jr, Kosinski M, Wada S, Gandek B (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51:1045–1053PubMedCrossRefGoogle Scholar
  14. 14.
    Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y (2003) Intra-individual variation in lumbar bone mineral density as a measure of spondylotic deformity in the elderly. J Bone Miner Metab 21:98–102PubMedCrossRefGoogle Scholar
  15. 15.
    Nathan H (1962) Osteophytes of the vertebral column: an anatomical study of their development according to age, race, and sex with considerations as to their etiology and significance. J Bone Joint Surg Am 44:243–268Google Scholar
  16. 16.
    Kellgren JH, Jeffrey MR, Ball J (eds) (1963) Atlas of standard radiographs of arthritis, vol 2. The epidemiology of chronic rheumatism. Blackwell, Oxford, pp 1–23Google Scholar
  17. 17.
    Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y (2008) Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine. J Int Med Res 36:932–941PubMedGoogle Scholar
  18. 18.
    Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG (1997) Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 275:112–114PubMedGoogle Scholar
  19. 19.
    Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15:284–289PubMedCrossRefGoogle Scholar
  20. 20.
    Ito A, Kumamoto E, Takeda M, Takeda M, Shibata K, Sagai H, Yosimura M (2000) Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 20:6302–6308PubMedGoogle Scholar
  21. 21.
    Orimo H, Fujita T, Yoshikawa M, Watanabe S, Otani M (1972) Ultimobranchial calcitonin of the eel, Anguilla japonica. Endocrinol Jpn 19:299–302PubMedGoogle Scholar
  22. 22.
    Yoshikawa S, Shiba M, Hoshino T, Igarashi M, Orimo H, Sakuma A, Tsuyama N (1983) Effect of eel calcitonin derivative (elcatonin) in osteoporosis. Nippon Seikeigeka Gakkai Zasshi 57:1717–1728PubMedGoogle Scholar
  23. 23.
    Fujita T, Fujii Y, Nakamura T, Miyauchi A, Takagi Y (2000) Effect of avicatonin (chicken carbocalcitonin) on galvanic skin response: a randomized, prospective, double-blind, controlled study for an objective assessment of pain. Calcif Tissue Int 66:243–247PubMedCrossRefGoogle Scholar
  24. 24.
    Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23:167–173PubMedCrossRefGoogle Scholar
  25. 25.
    Ohbayashi H (2009) Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis. Nippon Rinsho 67:206–212. doi:10.1007/s00774 (in Japanese)Google Scholar
  26. 26.
    Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2011

Authors and Affiliations

  • Takuo Fujita
    • 1
    • 2
  • Mutsumi Ohue
    • 1
  • Mikio Nakajima
    • 1
  • Yoshio Fujii
    • 2
  • Akimitsu Miyauchi
    • 3
  • Yasuyuki Takagi
    • 4
  1. 1.Katsuragi HospitalKishiwadaJapan
  2. 2.Calcium Research InstituteKishiwadaJapan
  3. 3.Miyauchi Medical ClinicTakatsukiJapan
  4. 4.National Hospital System Hyogo Chuo HospitalSandaJapan

Personalised recommendations